Pub. Date : 2014 Nov
PMID : 25142093
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. | Vitamin K | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | Interindividual variations in dose requirements of oral vitamin K antagonists (VKA) are attributed to several factors, including genetic variant alleles of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9), but also interaction with co-medications. | Vitamin K | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | Interindividual variations in dose requirements of oral vitamin K antagonists (VKA) are attributed to several factors, including genetic variant alleles of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9), but also interaction with co-medications. | Vitamin K | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |